Takeda Pharmaceutical Company Limited (TKPHF)
| Previous close | 26.52 |
| Open | 26.52 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 26.52 - 26.52 |
| 52-week range | 26.25 - 34.47 |
| Volume | |
| Avg. volume | 9,979 |
| Market cap | 41.607B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 36.33 |
| EPS (TTM) | 0.73 |
| Earnings date | N/A |
| Forward dividend & yield | 1.24 (4.68%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
Business WireTakeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
CAMBRIDGE, Mass., April 08, 2024--Takeda (TSE:4502/NYSE:TAK) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility (CSR) program. To create greater impact and foster equity in under-resourced communities, the company is focusing its philanthropic efforts on the two areas of Food is Health and Building STEM (Science, Technology, Engineering and Math) Foundations and p
Barrons.comARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
RA Capital increased its stake in biopharmaceutical firm ARS. Bain Capital lowered its stake in pharmaceutical firm Nuvalent.
PR NewswireEmpathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE. The initiative, focused on raising awareness of the difficult symptoms of Inflammatory Bowel Disease (IBD), entailed an immersive 24-hour simulation that generated a deeper understanding of how the disease affects the daily lives of patients.
